SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CervoMed Presents Interim Neflamapimod Biomarker Data at CTAD 2026

CervoMed said interim data show neflamapimod reduces a neurodegeneration biomarker in nonfluent variant primary progressive aphasia.

CRVO

Related stories